Fresh analysis reveals that individuals who discontinue popular weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who end traditional lifestyle programs.
Published data in a prominent medical journal shows that while obese people frequently drop a large proportion of their body weight while on the medication, the mass comes back at an average rate of nearly a kilo each month once they quit.
"Individuals buying these treatments need to be cognizant of the potential of fast weight regain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery implies a return to starting mass in about 18 months.
Comparing Treatments
The study, which looked at dozens of studies involving thousands of participants, contrasted the outcomes of these new drugs with other pills.
Scientists point out that people who shed pounds through dieting generally experience a more gradual weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Quick Regain
Experts suggest the mode of action of the drugs accounts for the heightened regain.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone levels far above than normal could lead to the system to produce less of its own natural GLP-1, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication results in hunger is uncontrolled, making overeating far more likely."
An Ongoing Condition?
The NHS recommend the injections for people with weight-linked medical conditions, alongside prescribed lifestyle changes.
Many experts contend that, given the significant potential of relapse, the therapy should be considered life-long.
This opinion is echoed by pharmaceutical companies, who note that the results "emphasize the long-term nature of excess weight," comparing it to managing diseases like hypertension.
Patient Testimonies
Individuals who have stopped the medication describe a powerful return of hunger.
"It was like something activating and you're instantly ravenous," described a patient.
This challenge is worsened if individuals have not developed lasting lifestyle or habit modifications during treatment.
Significant Adoption
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is greater among females than males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than the NHS.
Finally, experts stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent solution and long-term success hinges on integrated behavioural management.
